After Varenicline, Hausen Pharmaceuticals is expected to win the first imitation of Cabozantinib tablets

A few days ago, the listing application (relevant acceptance number: CYHS2000663/664) of the 3 generic generic drug "Carbotinib Malate Tablets" in Hausen Pharmaceuticals changed its status in NMPA to "Under Approval", and it is expected that it will be formally approved in the near future

Cabozantinib is a multi-target small molecule tyrosine kinase inhibitor.

Cometriq was approved by the FDA in November 2012 for the treatment of unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)

Cabometyx was used by the FDA in April 2016 for patients with advanced renal cell carcinoma (RCC) who had previously failed vascular endothelial growth factor (VEGF) targeted therapy.

In addition, the original research Cabozantinib has also been developed for the treatment of non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, bowel cancer and other cancers

The original research Cabozantinib was developed by Exelixis

In China, the original Cabozantinib has not yet been approved, and the original Cabozantinib tablet is in Phase 3 clinical trials, and its indication is combined with Atezolizumab for advanced hepatocellular carcinoma that has not previously received systemic anti-cancer treatment

At present, a number of domestic companies have set up the cabozantinib generic drug market.

Hausen Pharmaceuticals is the first domestic company to submit an application for the listing of a generic version of Cabozantinib Malate Tablets.

As of now, Hausen Pharmaceuticals has won the first imitation of Varenicline in 2021

In addition, the 2021 class of drugs Stockhausen medicine Amy tenofovir sheet (also called: Amy Diaminodiphenol tenofovir tablets) are approved domestic, for adults with chronic indications